Chronic neutrophilic leukemia interventions: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Bot: Removing from Primary care
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Chronic neutrophilic leukemia}}
{{Chronic neutrophilic leukemia}}
{{CMG}}; {{AE}} {{Homa}}
{{CMG}}; {{AE}} {{Homa}}; {{GRR}} {{Nat}}


==Overview==
==Overview==
There are no recommended therapeutic interventions for the management of [disease name].
[[Hematopoietic stem cell transplantation|Hematopoitic stem cell transplant]] is the mainstay of treatment for CNL patients. It is recommended that every [[Patient|patients]] that are qualified for HSCT, take this treatment. Since, the therapy in [[blast]] phases has the poor [[outcome]]<nowiki/>s, HSCT should be started as soon as possible in the [[disease]] course, before [[blast]] [[transformation]]. [[Splenic]] irradiation was used as a [[palliative]] [[treatment]] in [[patient]]<nowiki/>s of CNL with [[splenomegaly]].
 
OR
 
[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
 
OR
 
The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
 
OR
 
The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.
 
OR
 
[Name of intervention] is the mainstay of treatment for [disease or malignancy].


==Indications==
==Indications==


The mainstay of treatment for TT is medical therapy.
*<nowiki/>[[Hematopoietic stem cell transplantation|Hematopoitic stem cell transplant]] (HSCT):  HSCT is the only potential therapeutic option for patients with CNL. It is recommended that every [[Patient|patients]] that are qualified for HSCT, take this treatment. Since, the therapy in [[blast]] phases has the poor [[outcome]]<nowiki/>s, HSCT should be started as soon as possible in the [[disease]] course, before [[blast]] [[transformation]].<ref name="ElliottHanson2004">{{cite journal|last1=Elliott|first1=M A|last2=Hanson|first2=C A|last3=Dewald|first3=G W|last4=Smoley|first4=S A|last5=Lasho|first5=T L|last6=Tefferi|first6=A|title=WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature|journal=Leukemia|volume=19|issue=2|year=2004|pages=313–317|issn=0887-6924|doi=10.1038/sj.leu.2403562}}</ref><ref name="KakoKanda2007">{{cite journal|last1=Kako|first1=Shinichi|last2=Kanda|first2=Yoshinobu|last3=Sato|first3=Tomohiko|last4=Goyama|first4=Susumu|last5=Noda|first5=Naohiro|last6=Shoda|first6=Eriko|last7=Oshima|first7=Kumi|last8=Inoue|first8=Morihiro|last9=Izutsu|first9=Koji|last10=Watanabe|first10=Takuro|last11=Motokura|first11=Toru|last12=Chiba|first12=Shigeru|last13=Fukayama|first13=Masashi|last14=Kurokawa|first14=Mineo|title=Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation|journal=American Journal of Hematology|volume=82|issue=5|year=2007|pages=386–390|issn=03618609|doi=10.1002/ajh.20805}}</ref><ref name="SzuberTefferi2018">{{cite journal|last1=Szuber|first1=Natasha|last2=Tefferi|first2=Ayalew|title=Chronic neutrophilic leukemia: new science and new diagnostic criteria|journal=Blood Cancer Journal|volume=8|issue=2|year=2018|issn=2044-5385|doi=10.1038/s41408-018-0049-8}}</ref><ref name="CigudosaMenezes2015">{{cite journal|last1=Cigudosa|first1=Juan C|last2=Menezes|first2=Juliane|title=Chronic neutrophilic leukemia: a clinical perspective|journal=OncoTargets and Therapy|year=2015|pages=2383|issn=1178-6930|doi=10.2147/OTT.S49688}}</ref><ref name="TabbaraZimmerman2002">{{cite journal|last1=Tabbara|first1=Imad A.|last2=Zimmerman|first2=Kathy|last3=Morgan|first3=Connie|last4=Nahleh|first4=Zeina|title=Allogeneic Hematopoietic Stem Cell Transplantation|journal=Archives of Internal Medicine|volume=162|issue=14|year=2002|pages=1558|issn=0003-9926|doi=10.1001/archinte.162.14.1558}}</ref>
*[[Hematopoietic stem cell transplantation|Hematopoitic stem cell transplant]] (HSCT):  HSCT is the only potential therapeutic option for patients with CNL. It is recommended that every [[Patient|patients]] that are qualified for HSCT, take this treatment. Since, the therapy in [[blast]] phases has the poor [[outcome]]<nowiki/>s, HSCT should be started as soon as possible in the disease course, before blast transformation.<ref name="ElliottHanson2004">{{cite journal|last1=Elliott|first1=M A|last2=Hanson|first2=C A|last3=Dewald|first3=G W|last4=Smoley|first4=S A|last5=Lasho|first5=T L|last6=Tefferi|first6=A|title=WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature|journal=Leukemia|volume=19|issue=2|year=2004|pages=313–317|issn=0887-6924|doi=10.1038/sj.leu.2403562}}</ref><ref name="KakoKanda2007">{{cite journal|last1=Kako|first1=Shinichi|last2=Kanda|first2=Yoshinobu|last3=Sato|first3=Tomohiko|last4=Goyama|first4=Susumu|last5=Noda|first5=Naohiro|last6=Shoda|first6=Eriko|last7=Oshima|first7=Kumi|last8=Inoue|first8=Morihiro|last9=Izutsu|first9=Koji|last10=Watanabe|first10=Takuro|last11=Motokura|first11=Toru|last12=Chiba|first12=Shigeru|last13=Fukayama|first13=Masashi|last14=Kurokawa|first14=Mineo|title=Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation|journal=American Journal of Hematology|volume=82|issue=5|year=2007|pages=386–390|issn=03618609|doi=10.1002/ajh.20805}}</ref><ref name="SzuberTefferi2018">{{cite journal|last1=Szuber|first1=Natasha|last2=Tefferi|first2=Ayalew|title=Chronic neutrophilic leukemia: new science and new diagnostic criteria|journal=Blood Cancer Journal|volume=8|issue=2|year=2018|issn=2044-5385|doi=10.1038/s41408-018-0049-8}}</ref><ref name="CigudosaMenezes2015">{{cite journal|last1=Cigudosa|first1=Juan C|last2=Menezes|first2=Juliane|title=Chronic neutrophilic leukemia: a clinical perspective|journal=OncoTargets and Therapy|year=2015|pages=2383|issn=1178-6930|doi=10.2147/OTT.S49688}}</ref><ref name="TabbaraZimmerman2002">{{cite journal|last1=Tabbara|first1=Imad A.|last2=Zimmerman|first2=Kathy|last3=Morgan|first3=Connie|last4=Nahleh|first4=Zeina|title=Allogeneic Hematopoietic Stem Cell Transplantation|journal=Archives of Internal Medicine|volume=162|issue=14|year=2002|pages=1558|issn=0003-9926|doi=10.1001/archinte.162.14.1558}}</ref>
**[[Complications]] and [[side effects]] of this [[therapy]] include:
 
***[[Infection]]
**complications and side effects of this therapy include:
***[[Veno-occlusive disease]]
***Infection
***Veno-occlusive disease
***Mucositis
***Mucositis
***Graft-versus-host disease (GVHD)
***[[Graft-versus-host disease]] (GVHD)
***Graft versus tumor effect
***Graft versus tumor effect
*[[Splenic]] [[irradiation]]
*[[Splenic]] [[irradiation]]: [[Splenic]] [[irradiation]] was used as a [[palliative]] [[treatment]] in [[patient|patien]]<nowiki/>[[patient|t]]<nowiki/>s of CNL with [[splenomegaly]].<ref>{{Cite journal
| author = [[W. You]] & [[I. M. Weisbrot]]
| title = Chronic neutrophilic leukemia. Report of two cases and review of the literature
| journal = [[American journal of clinical pathology]]
| volume = 72
| issue = 2
| pages = 233–242
| year = 1979
| month = August
| pmid = 289288
}}</ref>


==References==
==References==
Line 40: Line 32:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category: (name of the system)]]
 
[[Category:Up-To-Date]]
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 20:57, 29 July 2020

Chronic neutrophilic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Chronic neutrophilic leukemia from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic neutrophilic leukemia interventions On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic neutrophilic leukemia interventions

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic neutrophilic leukemia interventions

CDC on Chronic neutrophilic leukemia interventions

Chronic neutrophilic leukemia interventions in the news

Blogs on Chronic neutrophilic leukemia interventions

Directions to Hospitals Treating Chronic neutrophilic leukemia

Risk calculators and risk factors for Chronic neutrophilic leukemia interventions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

Hematopoitic stem cell transplant is the mainstay of treatment for CNL patients. It is recommended that every patients that are qualified for HSCT, take this treatment. Since, the therapy in blast phases has the poor outcomes, HSCT should be started as soon as possible in the disease course, before blast transformation. Splenic irradiation was used as a palliative treatment in patients of CNL with splenomegaly.

Indications

References

  1. ↑ Elliott, M A; Hanson, C A; Dewald, G W; Smoley, S A; Lasho, T L; Tefferi, A (2004). "WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature". Leukemia. 19 (2): 313–317. doi:10.1038/sj.leu.2403562. ISSN 0887-6924.
  2. ↑ Kako, Shinichi; Kanda, Yoshinobu; Sato, Tomohiko; Goyama, Susumu; Noda, Naohiro; Shoda, Eriko; Oshima, Kumi; Inoue, Morihiro; Izutsu, Koji; Watanabe, Takuro; Motokura, Toru; Chiba, Shigeru; Fukayama, Masashi; Kurokawa, Mineo (2007). "Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation". American Journal of Hematology. 82 (5): 386–390. doi:10.1002/ajh.20805. ISSN 0361-8609.
  3. ↑ Szuber, Natasha; Tefferi, Ayalew (2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer Journal. 8 (2). doi:10.1038/s41408-018-0049-8. ISSN 2044-5385.
  4. ↑ Cigudosa, Juan C; Menezes, Juliane (2015). "Chronic neutrophilic leukemia: a clinical perspective". OncoTargets and Therapy: 2383. doi:10.2147/OTT.S49688. ISSN 1178-6930.
  5. ↑ Tabbara, Imad A.; Zimmerman, Kathy; Morgan, Connie; Nahleh, Zeina (2002). "Allogeneic Hematopoietic Stem Cell Transplantation". Archives of Internal Medicine. 162 (14): 1558. doi:10.1001/archinte.162.14.1558. ISSN 0003-9926.
  6. ↑ W. You & I. M. Weisbrot (1979). "Chronic neutrophilic leukemia. Report of two cases and review of the literature". American journal of clinical pathology. 72 (2): 233–242. PMID 289288. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_neutrophilic_leukemia_interventions&oldid=1636102"